Effects of gastric inhibitory polypeptide (GIP) and related analogues on glucagon release at normo- and hyperglycaemia in Wistar rats and isolated islets

Biological Chemistry

Volumn 389, Issue 2, 2008, Pages 189-193

  Cassidy, Roslyn S ^a   Irwin, Nigel ^a   Flatt, Peter R ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

GIP analogue; Glucagon; Glucose dependent insulinotropic polypeptide (GIP); Islet

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; IN VIVO STUDY; MALE; NONHUMAN; PANCREAS ISLET CELL; PRIORITY JOURNAL; RAT;

ANIMALS; BLOOD GLUCOSE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; HYPERGLYCEMIA; ISLETS OF LANGERHANS; RATS; RATS, WISTAR; STRUCTURE-ACTIVITY RELATIONSHIP;

RATTUS; RATTUS NORVEGICUS;

EID: 38649113286     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/BC.2008.019     Document Type: Article

References (24)

1. Burington, R.S. (1973). Handbook of Mathematical Tables and Formulae (New York, USA: McGraw-Hill).
2. Creutzfeldt, W. (2001). The entero-insular axis in type 2 diabetes - incretins as therapeutic agents. Exp. Clin. Endocrinol. Diabetes 109, S288-303.
3. Creutzfeldt, W. and Nauck, M.A (1992). Gut hormones and diabetes mellitus. Diabetes Metab. Rev. 8, 149-177.
4. Deacon, C.F. (2004). Circulation and degradation of GIP and GLP-1. Horm. Metab. Res. 36, 761-765.
5. Dupré, J., Caussignac, Y., McDonald, T.J., and Van Vliet, S. (1991). Stimulation of glucagon secretion by gastric inhibitory polypeptide in patients with hepatic cirrhosis and hyperglucagonemia. J. Clin. Endocrinol. Metab. 72, 125-129.
6. Gault, V.A., O'Harte, F.P.M., Harriott, P., and Flatt, P.R. (2002). Characterization of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent insulinotropic polypeptide. Biochem. Biophys. Res. Commun. 290, 1420-1426.
7. Gault, V.A., O'Harte, F.P., and Flatt, P.R. (2003). Glucose-dependent insulinotropic polypeptide (GIP): anti-diabetic and antiobesity potential? Neuropeptides 37, 253-263.
8. Gault, V.A., McClean, P.L., Cassidy, R.S., Irwin, N., and Flatt, P.R. (2007). Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets. Diabetologia 50, 1752-1762.
9. Green, B.D., Gault, V.A., O'Harte, F.P., and Flatt, P.R. (2004). Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents. Curr. Pharm. Des. 10, 3651-3662.
10. Irwin, N., Green, B.D., Mooney, M.H., Greer, B., Harriott, P., Bailey, C.J., Gault, V.A., O'Harte, F.P., and Flatt, P.R. (2005). A novel, long-acting agonist of glucose-dependent insulinotropic polypeptide suitable for once-daily administration in type 2 diabetes. J. Pharmacol. Exp. Ther. 314, 1187-1194.
11. Irwin, N., Clarke, G.C., Green, B.D., Greer, B., Harriott, P., Gault, V.A., O'Harte, F.P., Flatt, P.R. (2006). Evaluation of the antidiabetic activity of DPP IV resistant N-terminally modified versus mid-chain acylated analogues of glucose-dependent insulinotropic polypeptide. Biochem. Pharmacol. 72, 719-728.
12. 3)GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice. Diabetologia 50, 1532-1540.
13. Kjems, L.L., Holst, J.J., Volund, A., and Madsbad, S. (2003). The influence of GLP-1 on glucose-stimulated insulin secretion: effects on β-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 52, 380-386.
14. Knudsen, L.B., Kiel, D., Teng, M., Behrens, C., Bhumralkar, D., Kodra, J.T., Holst, J.J., Jeppesen, C.B., Johnson, M.D., de Jong, J.C., et al. (2007). Small-molecule agonists for the glucagon-like peptide 1 receptor. Proc. Natl. Acad. Sci. USA 104, 937-942.
15. Lacy, P.E. and Kostianovsky, M. (1967). Method for the isolation of intact islets of Langerhans from the rat pancreas. Diabetes 16, 35-39.
16. Meier, J.J., Hücking, K., Holst, J.J., Deacon, C.F., Schmiegel, W.H., and Nauck, M.A. (2001). Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes. Diabetes 50, 2497-2504.
17. Meier, J.J., Nauck, M.A., Siepmann, N., Greulich, M., Holst, J.J., Deacon, C.F., Schmidt, W.E., and Gallwitz, B. (2003a). Similar insulin secretory response to a gastric inhibitory polypeptide bolus injection at euglycemia in first-degree relatives of patients with type 2 diabetes and control subjects. Metabolism 52, 1579-1585.
18. Meier, J.J., Gallwitz, B., Siepmann, N., Holst, J.J., Deacon, C.F., Schmidt, W.E., and Nauck, M.A. (2003b). Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia 46, 798-801.
19. Meier, J.J., Deacon, C.F., Schmidt, W.E., Holst, J.J., and Nauck, M.A. (2007). Suppression of glucagon secretion is lower after oral glucose administration than during intravenous glucose administration in human subjects. Diabetologia 50, 806-813.
20. Nauck, M.A., Heimesaat, M.M., Orskov, C., Holst, J.J., Ebert, R., and Creutzfeldt, W. (1993). Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J. Clin. Invest. 91, 301-307.
21. O'Harte, F.P., Gault, V.A., Parker, J.C., Harriott, P., Mooney, M.H., Bailey, C.J., and Flatt, P.R. (2002). Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP. Diabetologia 45, 1281-1291.
22. Ørskov, C., Holst, J.J., and Nielsen, O.V. (1988). Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107)amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology 123, 2009-2013.
23. Pederson, R.A. and Brown, J.C. (1976). The insulinotropic action of gastric inhibitory polypeptide in the perfused isolated rat pancreas. Endocrinology 99, 780-785.
24. Pederson, R.A. and Brown, J.C. (1978). Interaction of gastric inhibitory polypeptide, glucose, and arginine on insulin and glucagon secretion from the perfused rat pancreas. Endocrinology 103, 610-615.